



MGC Pharmaceuticals Ltd
ABN 30 116 800 269

Level 7, 1008 Hay Street
Perth WA 6000
PO Box 7209
Cloisters Square WA 6850

Ph +61 8 9389 2000
Fax +61 8 9389 2099
info@mgcpharma.com.au

27 January 2016

ASX Code: MXC

Conditional Reinstatement Letter Issued

MGC Pharmaceuticals Limited (“the Company”) has received its Conditional Reinstatement letter from the ASX and is finalising the re-compliance documentation this week, including issue of the Prospectus Shares, completing the MGC acquisition and issue of shares to the Vendors.

The Company and Board now expects to be reinstated for trading on the ASX as MGC Pharmaceuticals Ltd (ASX: MXC) in the coming week. As soon as the final relisting date is confirmed by the ASX, the Company will immediately update the market and MXC shareholders.

-Ends-

About MGC Pharmaceuticals Ltd

MGC is EU based specialist medical and cosmetic cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabinoid resin extract (“CBD”) to the growing European cosmetics and medical markets.